EX-99.1

Exhibit 99.1

LOGO

Results of General Meeting

1 November 2021

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its general meeting held today, 1 November 2021, all resolutions set out in the notice of meeting were duly passed on a poll.

The votes were as follows:


Special Resolution	Votes for		%		Votes against		%		Votes total		% of ISC voted		Votes withheld
1 – Approve the cancellation of the admission to trading on AIM of the ordinary shares of nominal value £0.05 each in the capital of the Company and authorise the directors of the Company to take all action reasonable or necessary to effect such cancellation		31,092,066		99.47		166,904		0.53		31,258,970		34.82		4,408,363
2 – Approve, conditional on the passing of Resolution 1, the amendment to the articles of association of the Company		31,354,885		99.89		34,007		0.11		31,388,892		35.00		4,278,441

The number of the Company’s ordinary shares in issue as at the date of the meeting was 89,784,720 ordinary shares of nominal value £0.05 each.

A vote withheld is not a vote in law and has not been counted in the total votes or the calculation of the proportion of votes for and against the resolutions.

The Company confirms that, as at today’s date, the timetable for the cancellation of the admission to trading on AIM of the Company’s ordinary shares is as follows:


Last date for receipt by Link Group from certificated shareholders of duly completed block transfer participation request forms and original share certificates		3 November 2021 at 1.00 p.m.

Last date for receipt by The Bank of New York Mellon from CREST holders of duly completed issuance forms		17 November 2021 at 3.00 p.m.

Expected date of issuance of ADSs to block transfer participants		24 November 2021

Expected date of posting of ADS confirmations to shareholders by The Bank of New York Mellon		24 November 2021

Last day of dealings in the Ordinary Shares on AIM		29 November 2021

Cancellation of admission to trading on AIM of the Ordinary Shares		30 November 2021 at 7.00 a.m.

Enquiries:


Silence Therapeutics plc Gem Hopkins, Head of IR & Corporate Communications		Tel: +1 (646) 637-3208

Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence		Tel: +44 (0) 20 7597 5970

European PR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com		Tel: +44 (0) 20 3709 5700